Letter: mesalazine-a safe drug with rare serious adverse events? Authors' reply
Open Access
- 1 June 2020
- journal article
- letter
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 51 (11), 1212
- https://doi.org/10.1111/apt.15748
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Letter: mesalazine-a safe drug with rare serious adverse events? Authors' replyAlimentary Pharmacology & Therapeutics, 2020
- Letter: mesalazine—a safe drug with rare serious adverse eventsAlimentary Pharmacology & Therapeutics, 2020
- Mesalamine-Associated Sinus BradycardiaClinical Journal of Sport Medicine, 2019
- Systematic review: safety of mesalazine in ulcerative colitisAlimentary Pharmacology & Therapeutics, 2018
- Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factorsPostgraduate Medicine, 2016
- Convincing Evidence from Controlled and Uncontrolled Studies on the Lipid-Lowering Effect of a StatinPublished by Wiley ,2012
- Once-Daily Dosing of Delayed-Release Oral Mesalamine (400-mg Tablet) Is as Effective as Twice-Daily Dosing for Maintenance of Remission of Ulcerative ColitisGastroenterology, 2010
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- ABC of clinical electrocardiography: Bradycardias and atrioventricular conduction blockBMJ, 2002
- SEVERE SYMPTOMATIC SINUS BRADYCARDIA ASSOCIATED WITH MESALAMINE USEThe American Journal of Gastroenterology, 1998